Oct 22, 2009 1
UK’s drug watchdog National Institute for Clinical Excellence (NICE) has advised against public funding of Tyverb® (lapatinib) on grounds of cost. The drug is a treatment for an aggressive form of advanced breast cancer (ErbB2-positive). Drug makers GSK say they are considering an appeal against the decision. Read the rest of this entry »
 |
Mackenzie Iarussi on Acupuncture Offers Relief to Breast Cancer Patients With Hot Flashes |
 |
hosting on cancer and sexuality (part 3) - what remedies are available for changes? |
 |
Dre Beats Headphons on novel agents and treatment of advanced NSLC |
 |
Antonello on No NHS Funding For Breast Cancer Drug Lapatinib |
 |
Incostress on cancer and sexuality (part 3) - what remedies are available for changes? |
Most Commented